Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer by Wang, Dian et al.
University of Kentucky
UKnowledge
Epidemiology Faculty Publications Epidemiology
2-5-2014
Type and dose of radiotherapy used for initial
treatment of non-metastatic prostate cancer
Dian Wang
Medical College of Wisconsin
Alex Ho
American College of Radiology
Ann S. Hamilton
University of Southern California
Xiao-Cheng Wu
Louisiana State University Health Sciences Center - Shreveport
Mary Lo
University of Southern California
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/epidemiology_facpub
Part of the Epidemiology Commons
This Article is brought to you for free and open access by the Epidemiology at UKnowledge. It has been accepted for inclusion in Epidemiology Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Wang, Dian; Ho, Alex; Hamilton, Ann S.; Wu, Xiao-Cheng; Lo, Mary; Fleming, Steven; Goodman, Michael; Thompson, Trevor; and
Owen, Jean, "Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer" (2014). Epidemiology Faculty
Publications. 4.
https://uknowledge.uky.edu/epidemiology_facpub/4
Authors
Dian Wang, Alex Ho, Ann S. Hamilton, Xiao-Cheng Wu, Mary Lo, Steven Fleming, Michael Goodman,
Trevor Thompson, and Jean Owen
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Notes/Citation Information
Published in Radiation Oncology, v. 9, no. 47.
© 2014 Wang et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated.
Digital Object Identifier (DOI)
http://dx.doi.org/10.1186/1748-717X-9-47
This article is available at UKnowledge: https://uknowledge.uky.edu/epidemiology_facpub/4
RESEARCH Open Access
Type and dose of radiotherapy used for initial
treatment of non-metastatic prostate cancer
Dian Wang1*, Alex Ho2, Ann S Hamilton3, Xiao-Cheng Wu4, Mary Lo3, Steven Fleming5, Michael Goodman6,
Trevor Thompson7 and Jean Owen2
Abstract
Background: We sought to describe patterns of initial radiotherapy among non-metastatic prostate cancer (PC)
patients by recurrence risk groups.
Methods: Medical records were abstracted for a sample of 9017 PC cases diagnosed in 2004 as a part of the Center
for Disease Control and Prevention’s Prostate and Breast Patterns of Care Study in seven states. Non-metastatic PC cases
are categorized as low-risk (LR), intermediate-risk (IR) or high-risk (HR) groups based on pretreatment PSA, tumor stage,
and Gleason score per 2002 NCCN guidelines. Univariate and multivariate analyses were employed to determine factors
associated with the type and dose of radiotherapy by the risk groups.
Results: Of the 9,017 patients, 3153 who received definitive radiotherapy either alone or in combination with hormone
therapy (HT) were selected for in-depth analysis. Multivariate models showed that LR patients were more likely to
receive seed implant brachytherapy (BT) than those in higher risk groups. Those in the IR group were most likely to
receive external beam radiotherapy (EBRT) combined with BT or high-dose radiotherapy. Use of HT in combination
with radiotherapy was more common in the IR and HR groups than for LR patients. Intensity modulated radiation
treatment (IMRT) was used to treat 32.6% of PC patients treated with EBRT, with the majority (60.6%) treated with
high-dose radiotherapy.
Conclusions: Radiotherapy types and dosage utilization varied by PC risk groups. Patients in IR were more likely
than those in LR or HR to receive high-dose radiotherapy. IMRT was used in about one third of patients to deliver
high-dose radiotherapy.
Keywords: Prostate cancer, Radiotherapy, Patterns of care study
Background
Definitive radiotherapy (RT), either alone or in combination
with hormone therapy (HT), has been commonly used
to treat patients with non-metastatic prostate cancer in
accordance with the National Comprehensive Cancer
Network (NCCN) guidelines [1]. However, multiple options
for initial treatment including external beam radiation
treatment (EBRT), brachytherapy, surgery or various com-
binations of these with or without HT exist for patients
with similar risk factors. In addition, treatment choice is
influenced by demographic and socioeconomic factors,
medical comorbidities and concerns about the adverse
effects of therapy [1]. Furthermore, new technologies and
therapies have been introduced into clinical practice. There
have been significant increases in the use of intensity
modulated radiation treatment (IMRT), and HT combined
with radiotherapy (RT) for non-metastatic PC. However,
population-based information on radiotherapy types and
dosages by NCCN recurrence risk groups is lacking in the
literature. Because population-based cancer registries do
not collect up-to-date radiotherapy data of these types
and dosage, special data collection is required to conduct
such analysis.
In response to suggestions by the Institute of Medicine
[2], the National Program of Cancer Registries (NPCR)
funded by the Center for Disease Control and Prevention
(CDC) undertook a multi-state Patterns of Care study to
evaluate the standard of practice for cancer treatment in a
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cross-section of the United States. A Prostate Cancer Data
Quality and Patterns of Care Study (POC BP) in 1997 was
previously reported [3]. Practice trends in PC were
described based on individual risk factors such as prostate
specific antigen (PSA), Gleason score and results (normal
or abnormal) of digital rectal examination (not clinical T
stage) [3]. The current study has expanded data routinely
collected by the State cancer registry for PC patients
diagnosed in 2004 in seven States (California, Georgia,
Kentucky, Louisiana, Minnesota, North Carolina, and
Wisconsin). We previously reported clinical and demo-
graphic factors associated with receipt of guideline con-
cordant initial therapy for localized PC [4]. The current
analysis evaluates the type and dose of radiotherapy
used for initial treatment of localized PC having different
risk estimates of recurrence as defined in the NCCN
guidelines [5].
Materials and methods
Prostate cancer patient records were re-abstracted from
a stratified sample of incident microscopically-confirmed
prostate cancer cases diagnosed in 2004 from seven states
(i.e., California, Georgia, Kentucky, Louisiana, Minnesota,
North Carolina, and Wisconsin) as part of the CDC’s
POC-BP conducted in 2007-2009. Cancer registry data
obtained by routine methods [6] were verified and supple-
mented by re-abstracting hospital records and by obtaining
additional treatment information from outpatient facilities
including physicians’ offices, ambulatory surgery centers,
radiation facilities, and long-term care facilities. Further
information was collected regarding the patient demo-
graphic characteristics, clinical features of the tumor,
work-up details, and the first course of cancer-directed
treatment (i.e. therapy regimen that was given at the
time of the initial diagnosis, prior to disease recurrence
or progression).
The sample methodology, the design of the POC-BP
study, and an analysis of cancer registry data quality
have been reported elsewhere [7,8]. Briefly, 11,679 PC
cases were randomly selected across strata defined by
race/ethnicity and state-specific factors, for example,
Appalachian vs. non-Appalachian region, type of facility,
or patient volume of the facility. Abstraction was com-
pleted for 77.2% (9,017) of the sampled cases. Of those,
350 patients with node positive (N1) or metastatic (M1)
disease, 162 with insufficient information for NCCN recur-
rence risk group classification and 33 who were deceased
within 6 months of diagnosis with no treatment was ex-
cluded from the analysis. A total of 3,153 of the remaining
8,472 patients who had RT as initial treatment were in-
cluded in an in-depth analysis. The study was approved by
institutional review boards at participating institutions,
from 6 of the 7 participating states (one was exempted),
and at CDC.
Patient socio-demographic factors
Age at diagnosis, race and ethnicity, marital status, and
health insurance coverage were abstracted from medical
records. Other information pertaining to the patient’s
census tract of residence was obtained from 2000 U.S.
Census data. The census tract-specific indicators included
urbanization (100% urban, 100% rural, urban/rural mix),
proportion of individuals in the working class (<66% vs.
66%+), proportion of the population below the federal
poverty level (<20% vs. 20%+), and proportion of persons
(>25 years of age) without a high school education (<25%
vs. 25%+).
Definition of clinical recurrence risk groups
Clinical recurrence risk groups were defined according to
the NCCN guidelines for Prostate Cancer (version 1.2002)
that were in effect at the time these patients were origin-
ally diagnosed [5]. Briefly, parameters used to characterize
the risk of recurrence includes pretreatment prostatic
specific antigen (PSA), clinical T stage and Gleason score
(GS) from needle biopsy samples. Patients in the low risk
group (LR) had T1-T2a tumors, GS 2-6, and PSA < 10 ng/
ml. The intermediate risk group (IR) include those with
T2b-T2c tumors or GS = 7 or PSA 10-20 ng/ml, and the
high/very high risk group (HR) had T3a-T4 tumors or GS
8-10 or PSA > 20 ng/ml. The American Joint Committee
on Cancer Clinical Staging System 6th edition [9] was used
to assign the clinical T stage.
Definition of comorbidity
The ACE-27 (Adult Comorbidity Evaluation-27) was used
to measure comorbidity burden because of its clinical
relevance and sensitivity [7]. This 26-item chart-based
comorbidity index was initially developed by Piccirillo
and colleagues [10] and has been subsequently validated
[11,12]. The index is based on 26 comorbid conditions,
with three grades of decompensation (or severity) [12] that
were present at or before the date of diagnosis. Therefore,
complications related to cancer and/or its treatment were
not scored as comorbidities. Overall the comorbidity
severity score for the ACE-27 (Severe, Moderate, Mild,
or None) used in this study was determined by the
highest ranking single condition, except when two or
more Grade 2 conditions occurred in different organ sys-
tems, in which case the overall comorbidity score was
classified as Severe (Grade 3).
Definition of initial treatment
Initial treatment is defined as treatment received within
the first six months following pathological diagnosis of
prostate adenocarcinoma. In this report, initial RT includes
EBRT alone or seed implant brachytherapy (BT) alone or a
combination of both with or without HT. High-dose-rate
brachytherapy data was not abstracted in all seven states
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Table 1 Patient and tumor characteristics by type of initial radiation treatment
Characteristics Total (%)* Patients (n)† BT alone (%)‡ EBRT alone (%)‡ EBRT+BT (%)‡ Others§ (%)‡
Total 100.0 8946 (3153) 26.1 54.9 17.6 1.4
States (p < 0.0001)¶
A 22.6 2025 (502) 20.9 67.1 8.3 3.7
B 22.7 2028 (906) 21.2 43.9 34.1 0.8
C 6.9 618 (174) 30.4 59.1 9.9 0.6
D 10.0 892 (586) 30.8 50.8 16.2 2.2
E 8.7 776 (251) 25.7 53.0 21.3 0.0
F 19.4 1739 (433) 26.7 57.4 15.9 0.0
G 9.7 868 (301) 40.3 49.8 8.1 1.8
Age (y) (p < 0.0001)¶
20–59 14.7 1316 (499) 27.8 43.5 27.4 1.3
60–69 37.7 3375 (1251) 29.5 49.4 20.1 1.0
70+ 47.6 4255 (1403) 22.8 62.7 12.7 1.8
Race (p < 0.0001)¶
White, non-Hispanic 72.4 6478 (1805) 28.4 52.1 18.4 1.1
Black, non-Hispanic 19.4 1737 (1002) 20.1 61.0 18.1 0.8
Hispanic 5.6 497 (195) 19.7 65.4 7.0 7.9
Asians/others 2.6 234 (151) 18.8 63.1 16.1 2.0
Marital status (p = 0.2000)¶
Single 22.6 1949 (730) 24.0 58.2 16.9 0.9
Married 77.4 6680 (2317) 27.0 53.2 18.3 1.5
Education§ (p < 0.0001)¶
Not undereducated 64.5 5751 (1787) 29.0 51.0 18.7 1.3
Undereducated 35.5 3166 (1357) 21.0 61.7 15.6 1.7
Working class (p = 0.0075)¶
Not working class 43.7 3893 (1203) 28.2 50.5 19.8 1.5
Working class 56.3 5025 (1941) 24.5 58.2 15.9 1.4
Urbanization (p = 0.3671)¶
Urban 48.5 4324 (1468) 26.4 54.7 17.2 1.7
Rural 15.4 1372 (525) 23.6 59.7 15.8 0.9
Urban-Rural mix 36.1 3221 (1151) 26.8 52.9 18.9 1.4
Poverty level (p = 0.0013)¶
Not in poverty level 81.1 7233 (2317) 27.1 53.2 18.4 1.3
In poverty level 18.9 1685 (827) 21.7 61.9 14.4 2.0
Health insurance (p = 0.0010)¶
Not insured 1.3 111 (50) 11.8 71.2 12.3 4.7
Public coverage 64.2 5535 (2009) 25.1 57.6 16.4 0.9
Private coverage 30.8 2660 (857) 27.8 48.4 21.5 2.3
Insurance, NOS 3.7 319 (131) 27.0 46.9 23.9 2.2
Piccirillo comorbidity score (p = 0.2893)¶
None 28.8 2515 (860) 29.0 51.6 17.7 1.7
Mild 55.2 4816 (1720) 26.5 53.7 18.6 1.2
Moderate 12.2 1060 (390) 21.2 62.1 15.6 1.1
Severe 3.8 327 (111) 22.1 56.8 18.9 2.2
Wang et al. Radiation Oncology 2014, 9:47 Page 3 of 10
http://www.ro-journal.com/content/9/1/47
and was therefore excluded for this analysis. The total dose
Gray (Gy) administered is abstracted from medical records
for patients who completed definitive EBRT only, but
the fractionation schedule was unknown. HT is defined
as receiving any type of anti-androgen therapy.
Statistical analysis
Data analyses are performed using statistical software
SAS v.9.2, and SUDAAN v.10 that handles complex
sample surveys and allows for weighted estimates. Categor-
ical variables are presented as unweighted numbers (nuw),
weighted numbers (nw) and percentages (%) of patients.
Unadjusted associations of socio-demographic and tumor
characteristics with treatment modality are examined by
chi-square tests. Multivariable logistic regression models
are constructed to investigate the association of initial RT
patterns of PC care with the recurrence risk groups.
Covariates included in the initial model are the seven
registries, patient socio-demographics (age, race and ethni-
city, marital status, education, employment, poverty level,
urbanization, health insurance) and co-morbidity. Those
covariates that do not show significant relationship in
the initial model are excluded in the final reported
model, except co-morbidity, since it is a clinically import-
ant factor that would determine a patient’s treatment.
Odds ratios (OR) and 95% confidence intervals (95% CI)
were calculated with results considered statistically signifi-
cant at a two-sided alpha-error level of <0.05.
Results
Among 8,472 patients with non-metastatic PC, 3,153
received definitive radiotherapy, either alone or in com-
bination with HT. The characteristics of study participants
are summarized in Table 1. The vast majority of patients
receiving RT (85.3%) were 60 years of age or older. Non-
Hispanic Whites accounted for approximately 70% of the
cases followed by non-Hispanic Black (19.4%), Hispanic
(5.6%) and others (2.6%). Of those receiving initial RT,
54.9% had EBRT alone, 26.1% received BT alone, 17.6%
had EBRT combined with BT, and 1.4% had an unknown
RT modality. Variations in the use of RT by modality are
evident among the participating study sites (e.g. combination
therapy was more likely to occur in Registry B, whereas
EBRT alone was the most common treatment in Registry
A). All socio-demographic characteristics evaluated, ex-
cept marital status and urbanization, were associated with
variations of initial RT modalities (p < 0.0001). Men aged
70+ years were more likely than younger men to receive
EBRT alone. Non-Hispanic whites had the highest propor-
tion receiving BT alone compared with other racial/ethnic
groups. Men living in high poverty areas were more likely
than their counterparts to receive EBRT alone.
Table 1 Patient and tumor characteristics by type of initial radiation treatment (Continued)
PSA (ng/ml) (p < 0.0001)¶
<10 72.1 6360 (2199) 32.7 47.9 18.3 1.1
10–20 18.4 1620 (574) 10.2 69.8 18.0 2.0
>20 9.5 841 (329) 5.8 78.3 13.9 2.0
TNM Clinical T stage (p < 0.0001)¶
Tx-T0 0.5 49 (18) 9.2 84.8 3.7 2.3
T1 64.8 5793 (2064) 31.3 51.5 16.2 1.0
T2 31.7 2832 (978) 18.2 58.9 21.0 1.9
T3-T4 3.0 268 (92) 0.0 80.1 16.0 3.9
Gleason score (p < 0.0001)¶
2–6 56.6 5020 (1732) 37.5 46.4 14.7 1.4
7 31.9 2836 (1020) 13.0 62.8 22.9 1.3
8-10 11.5 1023 (375) 3.9 75.4 18.6 2.1
Recurrence risk group (p < 0.0001)¶
LR 41.2 3684 (1257) 45.2 39.9 13.8 1.1
IR 40.1 3583 (1261) 16.1 60.0 22.5 1.4
HR 18.8 1680 (635) 5.2 76.8 15.7 2.3
BT, brachytherapy; EBRT, external beam radiation therapy; LR, low risk group; IR, intermediate risk group; HR, high/very high risk group.
(*) Column percentages based on weighted number of patients.
(†) Weighted number of patients, with unweighted number in parentheses.
(‡) Row percentages based on weighted number of patients.
(§) Included those with no RT, had RT but with unknown modality, and unknown if they had RT.
(¶) p-values (Chi-square test to measure of association between RT treatment and each of socio-demographic/clinical variables).
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There was no significant relationship (p = 0.2893) be-
tween comorbidity severity and RT modality (Table 1). All
tumor characteristics, however, are significantly associated
with the type of RT received (p < 0.0001). Patients with
PSA <10 ng/ml were more likely to receive BT only,
whereas those with PSA >20 ng/ml were more likely to
receive EBRT. Similarly, those with lower T stage (T1-2)
had a higher likelihood of receiving BT only. In contrast,
over 80% of those with T3-T4 disease received EBRT. More
patients with T2 tumors received EBRT+BT than those
with higher or lower T stages, and similarly, EBRT+BT was
more commonly used for patients with a GS 7 than among
those with higher or lower GS.
Among patients receiving initial RT, 41.2%, 40.1%, and
18.8% were in the LR, IR and HR groups, respectively.
LR patients were more likely to receive BT, while EBRT
was more likely to occur among those in the IR and HR
groups. Receipt of EBRT+BT, suggestive of high-dose
RT, was most common in the IR group.
Detailed information on receipt of EBRT, EBRT+BT
or BT with/without HT by characteristics of patients is
summarized in Table 2. Tumor characteristics such as
T stage and GS are significant determinants of RT type
either alone or in combination with HT. Men receiving
RT (any type)+HT were more likely to have higher PSA
levels, T stage, and GS than those who received RT alone.
Significant differences are also observed across the
recurrence risk groups in the percent of patients receiving
RT alone versus RT+HT (Table 2). Patients receiving RT
(any type)+HT were more likely to be in the HR group
Table 2 Comorbidity and tumor characteristics of patient by initial radiation treatment modality during the 6 months
after diagnosis
Comorbidity/tumor
characteristics
EBRT alone
(%)*
EBRT+HT
(%)*
EBRT+BT
(%)*
EBRT+BT+HT
(%)*
BT alone
(%)*
BT+HT
(%)*
RT (Type unknown)±HT
(%)*
Total 24.5 30.4 10.5 7.1 17.9 8.2 1.4
Piccirillo comorbidity score
(nw = 8718, p = 0.5183)
†
None 28.5 26.6 31.0 24.6 33.9 26.7 35.3
Mild 54.4 54.9 55.0 60.2 52.9 60.9 49.3
Moderate 12.9 14.8 10.5 10.6 10.1 9.1 9.6
Severe 4.2 3.7 3.5 4.6 3.1 3.3 5.8
PSA (ng/ml) (nw = 8822,
p < 0.0001)†
<10 76.3 52.2 83.0 60.9 92.7 86.3 59.0
10–20 20.5 25.7 13.6 25.8 5.9 10.1 27.0
>20 3.2 22.1 3.4 13.3 1.4 3.6 14.0
Clinical T stage (nw = 8941,
p < 0.0001)†
Tx-T0 0.8 0.9 0.0 0.3 0.1 0.4 0.9
T1 70.5 53.0 66.3 49.4 77.0 79.2 46.7
T2 27.4 39.2 32.4 45.5 22.9 20.4 44.1
T3-T4 1.3 6.9 1.3 4.8 0.0 0.0 8.3
Gleason score (nw = 8879,
p < 0.0001)†
2–6 66.7 32.3 56.4 32.6 84.6 76.7 55.1
7 29.5 42.2 38.0 46.0 14.0 20.7 27.9
8–10 3.8 25.5 5.6 21.4 1.4 2.6 17.0
Recurrence risk group (nw = 8946,
p < 0.0001)†
LR 46.7 16.5 43.9 15.0 75.4 62.7 31.2
IR 46.1 41.8 47.3 56.7 21.8 31.4 38.8
HR 7.2 41.7 8.8 28.3 2.8 5.9 30.0
LR, low risk group; IR, intermediate risk group; HR, high/very high risk group; BT, brachytherapy; EBRT, external beam radiotherapy; HT, hormone therapy.
RT, radiotherapy.
(*) Column percentages based on weighted number of patients, except the first row (Total) which was a row percentage.
(†) p-values (Chi-square test to measure of association between each of comorbidity/tumor characteristics variables and initial treatment modality).
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than those who received RT alone. A similar trend was also
observed in the IR group. By contrast, patients receiving
RT alone were more likely to be in the LR group than those
who received RT+HT.
Results of multivariate logistic models
Multivariate logistic models were constructed to measure
the relationship between RT modality and recurrence risk
groups, adjusting for comorbidity and sociodemographic
factors (Figure 1). Results of this analysis show that com-
pared with LR group, patients in higher risk groups were
less likely to receive BT alone vs. EBRT (IR: OR = 0.26,
95% CI = 0.20-0.33; HR: OR = 0.06, 95% CI = 0.04-0.10).
However, those with IR were more likely than those with
LR to receive EBRT + BT (OR = 1.35, 95% CI = 1.01-1.80).
Patients in IR (OR = 2.61, 95% CI = 2.10-3.24) or HR
(OR = 12.57, 95% CI = 9.26-17.06) were more likely to re-
ceive RT plus HT compared with patients in LR.
The total dose of EBRT received (<70 Gy, 70-74 Gy,
or ≥75 Gy) by sociodemographic, clinical and tumor
characteristics, and recurrence risk group are shown in
Table 3. Over half (53%) received less than 70 Gy and a
quarter received 70-74 Gy while only 22% received a
high dose (≥75 Gy). Of those receiving the high dose,
60.6% were treated with IMRT compared with 22.6% of
those treated to 70-74 Gy and 26.7% of those treated
with low dose (<70 Gy) (Table 4).
The percent of patients receiving different levels of
radiation dose varied among regions and states. The
proportion of men receiving the high dose (≥75 Gy)
varied from a high of 41% in Region E to a low of 14% in
Region C (p < 0.0001). The dose received was not related
to marital status or proportion of working class residents
in the patient’s census tract; however, those in areas with
population indicators reflecting a higher socioeconomic
status (i.e., higher proportion of persons with at least a
high school degree and lower proportion living under
the poverty level) as well as those living in an urbanized
area were more likely to receive a high dose of ≥75 Gy
(p < 0.03). Clinical T stage and ACE-27 comorbidity score
were not associated with level of total EBRT dose ad-
ministered; however, patients with high pre-treatment
PSA of >20 were less likely to receive high dose EBRT
than their counterparts with lower pre-treatment PSA
of ≤ 20 (p = 0.0016). Higher Gleason score was associated
with a higher percentage of low dose EBRT and less
medium dose EBRT (70-74 Gy) [p = 0.0007]. The percent-
ages of high dose EBRT were similar across the Gleason
score groups.
Total dose received also varied significantly across the
recurrence risk groups (p = 0.0001) (Table 3). Patients in
the HR group were the most likely (61.8%) to receive the
lowest dose (<70 Gy), compared to 53.8% and 44.3% of
those with IR and LR, respectively. Intermediate dose
(70-74 Gy) was more often used for LR patients, while
the high dose (≥75 Gy) radiation was more often used
for IR patients.
Discussion
The association of PC treatment with clinical factors such
as PSA, GS and clinical T stage or modified risk groups
has been reported previously for PC cases diagnosed in
1997 [3], 1999 [13], 2002 [14], 2013 [15]. For purposes of
PC management, however, it is important to examine
patterns of care according to the NCCN recurrence risk
groups, which already take into account the three most
important predictors of prognosis (i.e., clinical T stage,
pretreatment PSA and biopsy GS). Although each of these
Adjusted Odds ratio and 95% CI*
(*) adjusted for states, age, race-ethnicity, and comorbidity
BT vs. 
EBRT
0.0 1.0 2.0 3.0 9 1311 17
EBRT+BT 
vs. EBRT
RT+HT 
vs. RT
IR vs. LR
HR vs. LR
Recurrence Risk GroupsModality
RT=Radiotherapy; BT=brachytherapy; EBRT=External beam 
radiotherapy; HT=hormone therapy
LR=low risk group; IR=intermediate risk group;HR=high risk group
Figure 1 Multivariate logistic models.
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Table 3 Patient and tumor characteristics by a total dose of external beam radiation therapy (EBRT) alone
<70 Gy 70–74 Gy 75+ Gy
Characteristics (%)* Patients (n)† (%)* Patients (n)† (%)* Patients (n)†
Total‡, n = 4611 (1636) 53.0 2444 (920) 25.0 1152 (382) 22.0 1015 (334)
States (p < 0.0001)§
A 32.2 369 (100) 41.5 476 (125) 26.3 302 (69)
B 74.3 645 (293) 9.8 85 (39) 15.9 138 (69)
C 58.5 204 (57) 27.5 96 (28) 14.0 49 (13)
D 57.7 253 (166) 26.7 117 (78) 15.6 68 (45)
E 46.2 188 (74) 13.0 53 (19) 40.8 167 (48)
F 59.5 584 (157) 22.4 221 (52) 18.1 177 (50)
G 48.0 201 (73) 24.8 104 (41) 27.2 114 (40)
Age (y) (p = 0.0156)§
20–59 64.6 345 (131) 15.2 81 (33) 20.2 108 (37)
60–69 53.5 837 (338) 25.5 400 (141) 21.0 330 (127)
70+ 50.3 1262 (451) 26.7 671 (208) 23.0 577 (170)
Race (p < 0.0001)§
White, non-hispanic (NH) 53.5 1706 (508) 24.4 777 (190) 22.1 703 (183)
Black, NH 59.8 603 (332) 21.2 213 (123) 19.0 191 (106)
Hispanic 32.1 93 (52) 38.8 112 (38) 29.1 84 (23)
Asians/others 32.9 42 (28) 38.5 50 (31) 28.6 37 (22)
Marital status (p = 0.8262)§
Single 55.0 586 (238) 23.8 253 (92) 21.2 225 (84)
Married 53.2 1773 (649) 23.8 795 (263) 23.0 766 (243)
Education¶ (p = 0.0279)§
Not undereducated 50.8 1417 (481) 24.6 685 (200) 24.6 688 (195)
Undereducated 56.3 1014 (435) 25.8 464 (181) 17.9 323 (138)
Working class (p = 0.0910)§
Not working class 48.9 908 (312) 26.3 487 (133) 24.8 461 (127)
Working class 55.7 1522 (604) 24.2 662 (248) 20.1 550 (206)
Urbanization (p = 0.0293)§
Urban 47.6 1023 (400) 28.3 608 (200) 24.1 519 (165)
Rural 57.4 454 (165) 22.7 179 (64) 19.9 157 (57)
Urban-Rural mix 57.8 954 (351) 21.9 362 (117) 20.3 335 (111)
Poverty level (p = 0.0255)§
Not in poverty level 51.6 1870 (644) 24.9 904 (268) 23.5 852 (254)
In poverty level 58.1 561 (272) 25.4 245 (113) 16.5 159 (79)
Health insurance (p = 0.0036)§
Not insured 58.7 46 (22) 22.7 18 (6) 18.6 14 (7)
Public coverage 56.9 1732 (664) 20.9 637 (229) 22.2 674 (232)
Private coverage 45.1 519 (179) 36.4 418 (117) 18.5 212 (65)
Insurance, NOS 61.6 87 (33) 16.5 23 (11) 21.9 31 (10)
Piccirillo comorbidity score (p = 0.0800)§
None 50.5 613 (221) 25.5 310 (94) 24.0 291 (88)
Mild 52.2 1273 (492) 24.8 604 (213) 23.0 560 (188)
Moderate 60.3 378 (143) 19.1 120 (44) 20.6 129 (42)
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factors independently predicts relapse-free survival,
multiple studies have demonstrated that the recurrence
risk groups, representing a combination of factors, better
categorize patients with different prognosis in order to
reliably compare the success of treatment regimens [1].
The current study examines the initial RT patterns in a
large number of study subjects with initial RT details
(dose and technique) by the NCCN recurrence risk group.
The results of this study reflect the major changes in
the radiotherapeutic management of localized PC in the
United States that have occurred. RT planning and delivery
systems have become more sophisticated and precise, and
have moved from conventional RT to IMRT. IMRT is able
to deliver a much higher conformal dose to tumor targets
than conventional RT through modulation of radiation
beam intensities in many different fields [16]. High-dose
RT is known to improve disease control in PC, particularly
with intermediate risk factors [17]. In this study based on
cases diagnosed in 2004, high-dose RT (≥75 Gy EBRT or
combination of EBRT and seed implant BT) was used
more often in the IR group than in the LR or HR groups
(Figure 1). IMRT was often utilized to deliver high dose in
patients receiving EBRT only. Use of high-dose RT for
patients in the IR group with the growing popularity of
IMRT has not been reported in previous patterns of care
studies [3,13-15]. IMRT was not commonly used until
the first decade of this century, and therefore might not be
a variable to be abstracted for analysis in previous studies.
Long-term results of various randomized trials from
the cooperative groups including the Radiation Therapy
Oncology Group (RTOG) and the European Organization
for the Research and Treatment of Cancer have indicated
clear advantages of combining RT with HT for patients
with high-risk localized PC [18,19]. In addition, results of
a randomized study [20] showed that addition of short-
term (6-month) HT to EBRT (70 Gy in 35 daily fractions)
conferred an overall survival benefit (88% for EBRT plus
HT versus 57% for RT alone) after a median follow-up of
4.52 years in 206 non-metastatic PC patients (majority in
the IR group). It appears that the results from these ran-
domized trials have influenced routine management of PC
in the community. In our study, patients in IR or HR were
more likely to receive RT plus HT than LR patients in this
study, even though use of RT combined with HT was not
Table 3 Patient and tumor characteristics by a total dose of external beam radiation therapy (EBRT) alone (Continued)
Severe 65.1 119 (46) 23.4 43 (11) 11.5 21 (10)
PSA (ng/ml) (p = 0.0016)§
<10 50.0 1446 (533) 27.3 787 (256) 22.7 656 (210)
10–20 53.7 556 (215) 21.2 220 (74) 25.1 259 (81)
>20 65.1 408 (158) 21.0 131 (49) 13.9 87 (40)
Clinical T stage (p = 0.1833)§
Tx-T0 26.1 9 (4) 24.3 9 (4) 49.6 18 (5)
T1 52.1 1477 (569) 26.2 741 (252) 21.7 613 (197)
T2 53.7 825 (299) 24.4 376 (115) 21.9 336 (115)
T3-T4 64.4 133 (48) 12.8 26 (11) 22.8 47 (17)
Gleason score (p = 0.0007)§
2–6 46.9 1033 (385) 30.5 670 (218) 22.6 498 (163)
7 57.6 958 (361) 20.5 341 (115) 21.9 365 (119)
8–10 61.4 441 (169) 17.8 128 (46) 20.8 150 (50)
Recurrence risk group (p = 0.0001)§
LR 44.3 620 (229) 34.0 477 (155) 21.7 304 (101)
IR 53.8 1071 (401) 21.9 435 (143) 24.3 484 (150)
HR 61.8 753 (290) 19.7 241 (84) 18.5 226 (83)
LR, low risk group; IR, intermediate risk group; HR, high/very high risk group.
(*) Row percentages based on weighted number of patients.
(†) Weighted number of patients, with unweighted number in parentheses.
(‡) Excluded 101 patients (unweighted) who did not have information on EBRT dose.
(§) p-values (Chi-square test to measure of association between EBRT dose and each of socio-demographic/clinical variables).
Table 4 Relationship between total EBRT dose and EBRT
modality
RT modality (p < 0.0001) <70 Gy 70–74 Gy 75+ Gy
non-IMRT 69.8* 77.4 32.0
IMRT 26.7 22.6 60.6
Unknown 3.5 0.0 7.4
Totals 100.0 100.0 100.0
(*) weighted%.
EBRT, external beam radiotherapy; IMRT, intensity modulated radiation treatment.
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recommended to treat patients in IR in the 2002 NCCN
guidelines. It is worth noting that the role of HT added
to high-dose RT in IR still remains unclear. RTOG is
currently investigating the addition of short-term HT to
high-dose RT to improve survival in patients with inter-
mediate risk factors.
One of the limitations of our study is the possible
underreporting of radiation and hormone treatment
derived from the registry data or data re-abstraction. In
addition, use of life expectancy as a key decision making
factor in determining the NCCN guideline care could not
be addressed in our analyses.
Conclusion
This is the largest patterns of care study to describe
specific types and doses of radiotherapy used to treat
prostate cancer patients in different NCCN recurrence
risk groups using state registry data. We found the use
of seed implant brachytherapy to be more common in
PC patients with low risk factors compared to patients in
the intermediate to high-risk groups, while radiotherapy
combined with hormone therapy was used more often in
patients with higher risk factors than in patients with low
risk group. High dose RT (≥75 Gy EBRT or EBRT com-
bined with seed implant brachytherapy) was more often
given to patients in the intermediate risk group than to
low-risk or high-risk patients. IMRT has been increasingly
accepted as the radiotherapy of choice and is often used
to deliver high-dose EBRT. The results of this study pro-
vide a basis for assessing the use of radiation therapy and
for monitoring trends in its delivery.
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